Upper extremity deep vein thrombosis: clinical and treatment characteristics.
We aimed to evaluate patients with upper extremity deep vein thrombosis (UEDVT) in terms of the risk factors, symptoms, clinical course, diagnostic approaches and treatment outcome. Thirty-six patients with a diagnosis of UEDVT, comprising 19 males (52.7%) and 17 females (47.3%), were included in the study; the mean (+/- SD) age was 54 +/- 12.3 years. The most common risk factor was central venous catheter use. The treatment protocol consisted of low molecular weight heparin for up to 7 days, followed by oral anticoagulants for up to 6 months. All patients were followed up for 1 year. More than 90% of the patients responded well to treatment. Nine patients (25%) died due to underlying diseases; no patients died secondary to UEDVT. None of the patients developed pulmonary embolus or recurrent deep venous thrombosis, and post-thrombotic syndrome was not observed. The mortality rate was related to the underlying diseases.
Karabay
O
O
Department of Heart and Vascular Surgery, Izmir Dokuz Eylul Medical Faculty, Izmir, Turkey. ozalp.karabay@deu.edu.tr
Yetkin
U
U
Onol
H
H
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage; D002405:Catheterization, Central Venous; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D034941:Upper Extremity / Q000473:pathology; D020246:Venous Thrombosis / Q000175:diagnosis* / Q000628:therapy*
D000925:Anticoagulants; D006493:Heparin